XTX Topco Ltd Invests $352,000 in Glaukos Corporation (NYSE:GKOS)

Key Points

• XTX Topco Ltd made an investment of approximately $352,000 in Glaukos Corporation by acquiring 3,577 shares during the 1st quarter, as reported in a recent SEC filing.
• Glaukos Corporation reported a 29.7% year-over-year increase in revenue, amounting to $124.12 million for the last quarter, with an EPS of ($0.24) which beat expectations.
• The stock currently holds a Moderate Buy average rating from analysts, with a target price of $127.42 after several analysts adjusted their price objectives.

XTX Topco Ltd purchased a new position in shares of Glaukos Corporation (NYSE:GKOS - Free Report) in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 3,577 shares of the medical instruments supplier's stock, valued at approximately $352,000.

Other institutional investors also recently made changes to their positions in the company. Invesco Ltd. raised its holdings in shares of Glaukos by 4.9% during the fourth quarter. Invesco Ltd. now owns 1,458,635 shares of the medical instruments supplier's stock valued at $218,708,000 after purchasing an additional 68,310 shares during the period. Gilder Gagnon Howe & Co. LLC grew its position in shares of Glaukos by 25.3% during the 4th quarter. Gilder Gagnon Howe & Co. LLC now owns 825,276 shares of the medical instruments supplier's stock valued at $123,742,000 after purchasing an additional 166,677 shares in the last quarter. Northern Trust Corp grew its position in Glaukos by 7.4% in the fourth quarter. Northern Trust Corp now owns 578,673 shares of the medical instruments supplier's stock worth $86,766,000 after acquiring an additional 40,052 shares in the last quarter. Principal Financial Group Inc. grew its position in Glaukos by 21.8% in the first quarter. Principal Financial Group Inc. now owns 327,036 shares of the medical instruments supplier's stock worth $32,187,000 after acquiring an additional 58,502 shares in the last quarter. Finally, Nuveen Asset Management LLC lifted its stake in Glaukos by 0.9% in the fourth quarter. Nuveen Asset Management LLC now owns 314,963 shares of the medical instruments supplier's stock worth $47,226,000 after purchasing an additional 2,665 shares during the last quarter. Institutional investors own 99.04% of the company's stock.

Analyst Upgrades and Downgrades

GKOS has been the topic of a number of research reports. Stifel Nicolaus reduced their target price on shares of Glaukos from $140.00 to $115.00 and set a "buy" rating on the stock in a report on Thursday, May 1st. Morgan Stanley cut their price target on shares of Glaukos from $110.00 to $72.00 and set an "underweight" rating on the stock in a research note on Tuesday, May 6th. BTIG Research reissued a "buy" rating on shares of Glaukos in a report on Monday, July 14th. Wells Fargo & Company increased their price objective on shares of Glaukos from $86.00 to $92.00 and gave the company an "equal weight" rating in a report on Thursday, July 31st. Finally, Stephens decreased their price target on shares of Glaukos from $140.00 to $115.00 and set an "overweight" rating on the stock in a research note on Friday, May 2nd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $127.42.

Glaukos Price Performance

Shares of NYSE:GKOS traded down $0.83 on Thursday, reaching $90.96. 324,211 shares of the company were exchanged, compared to its average volume of 960,914. Glaukos Corporation has a 1-year low of $77.10 and a 1-year high of $163.71. The company has a current ratio of 5.51, a quick ratio of 4.69 and a debt-to-equity ratio of 0.09. The company has a 50-day moving average of $96.93 and a 200-day moving average of $104.67. The firm has a market cap of $5.22 billion, a price-to-earnings ratio of -55.16 and a beta of 0.78.

Glaukos (NYSE:GKOS - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The medical instruments supplier reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.02. The business had revenue of $124.12 million for the quarter, compared to analyst estimates of $115.49 million. Glaukos had a negative net margin of 21.43% and a negative return on equity of 8.59%. The company's revenue was up 29.7% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.52) EPS. Equities analysts forecast that Glaukos Corporation will post -1.08 earnings per share for the current fiscal year.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.